Patents Assigned to The Beth Israel Hospital Association
-
Patent number: 6770272Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: GrantFiled: May 14, 2002Date of Patent: August 3, 2004Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20030223970Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65° C. for 15 minutes, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.Type: ApplicationFiled: March 12, 2001Publication date: December 4, 2003Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventors: Terry B. Storm, Towia Libermann
-
Publication number: 20030050271Abstract: This invention pertains to a method of infecting an organ or a tissue other than a liver with an effective amount of a vector carrying genetic material of interest. This invention features a method of infecting kidney cells by introducing into the vasculature of a kidney a vector carrying genetic material of interest and maintaining the vector in contact with the renal vasculature for a period of time sufficient to allow infection of kidney cells with an effective amount of the vector, and under conditions which protect the kidney from ischemic damage. This method allows for infection of a significant number of renal endothelial cells. The method of the invention can be used for both in vivo and ex vivo applications.Type: ApplicationFiled: July 10, 2002Publication date: March 13, 2003Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventor: Vikas Sukhatme
-
Publication number: 20030026778Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.Type: ApplicationFiled: May 14, 2002Publication date: February 6, 2003Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20030003098Abstract: Disclosed are methods for inhibit rejection of a graft in a patient. The methods involve treating the graft with a molecule which binds to a co-stimulatory protein of antigen-presenting cells. Useful molecules include chimeras having enzymatically inactive polypeptides bonded to polypeptides which bind to co-stimulatory proteins of antigen-presenting cells. Also disclosed, are chimeric molecules composed of lytic IgG Fc bonded to CD2, CD28, CD40L, or CTLA-4. In addition, disclosed are methods for inhibiting rejection of a graft in a patient; the methods involve treating the brain-dead, beating heart donor of the graft, prior to removal of the graft from the donor, to render the graft less susceptible to rejection by the patient.Type: ApplicationFiled: August 26, 2002Publication date: January 2, 2003Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventor: Terry B. Strom
-
Publication number: 20020173628Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: ApplicationFiled: May 14, 2002Publication date: November 21, 2002Applicant: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20020164311Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65° C. for 15 minutes, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.Type: ApplicationFiled: March 12, 2001Publication date: November 7, 2002Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventors: Terry B. Storm, Towia Libermann
-
Patent number: 6410008Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: GrantFiled: December 12, 1994Date of Patent: June 25, 2002Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Patent number: 6403077Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.Type: GrantFiled: November 6, 1997Date of Patent: June 11, 2002Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Patent number: 6113900Abstract: Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as monoclonal antibodies or IL-2, optionally linked to a cytotoxin. Administration of the agents inhibits the proliferation of lymphocytes expressing the IL-2 receptor and thus mitigates unwanted immune responses.Type: GrantFiled: November 21, 1997Date of Patent: September 5, 2000Assignee: The Beth Israel Hospital AssociationInventor: Terry B. Strom
-
Patent number: 6099542Abstract: The present invention provides catheter apparatus and catheterization methodology for generating an arteriovenous fistula or a veno-venous fistula on-demand between closely associated blood vessels and at a chosen anatomic site in-vivo. The catheter apparatus is preferably employed in pairs, each catheter of the pair being suitable for percutaneous introduction into and extension through a blood vessel. The catheterization methodology employs the catheter apparatus preferably in conjunction with conventional radiological techniques in order to place, verify, and confirm a proper alignment, orientation, and positioning for the catheters in-vivo prior to activating the perforation means for generating a fistula.Type: GrantFiled: August 17, 1998Date of Patent: August 8, 2000Assignee: Beth Israel Hospital Association Inc.Inventors: William E. Cohn, Ducksoo Kim
-
Patent number: 6068837Abstract: Methods and pharmaceutical compositions for modifying the mesothelial cells of a mammalian recipient in situ are provided. The methods include forming a mesothelial cell expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial cells). The mesothelial cell expression system is useful for the localized and systemic delivery of therapeutic agents in situ.Type: GrantFiled: December 3, 1997Date of Patent: May 30, 2000Assignee: Beth Israel Hospital AssociationInventors: Ty Robert Shockley, Robert William Jackman, Janice Ann Nagy
-
Patent number: 5958403Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.Type: GrantFiled: July 11, 1994Date of Patent: September 28, 1999Assignee: Beth Israel Hospital AssociationInventors: Terry Strom, Towia Libermann
-
Patent number: 5916559Abstract: A method of lysing unwanted, non-malignant cells in a mammal, the cells having on their surfaces a receptor for a growth factor, and the method including administering to the mammal a cell-lysing amount of a substance characterized in that it has specific affinity for the receptor of the growth factor and has the ability to effect the lysis of the cells.Type: GrantFiled: December 11, 1996Date of Patent: June 29, 1999Assignee: The Beth Israel Hospital AssociationInventor: Terry B. Strom
-
Patent number: 5869230Abstract: This invention pertains to a method of infecting an organ or a tissue other than a liver with an effective amount of a vector carrying genetic material of interest. This invention features a method of infecting kidney cells by introducing into the vasculature of a kidney a vector carrying genetic material of interest and maintaining the vector in contact with the renal vasculature for a period of time sufficient to allow infection of kidney cells with an effective amount of the vector, and under conditions which protect the kidney from ischemic damage. This method allows for infection of a significant number of renal endothelial cells. The method of the invention can be used for both in vivo and ex vivo applications.Type: GrantFiled: March 30, 1995Date of Patent: February 9, 1999Assignee: Beth Israel Hospital AssociationInventor: Vikas P. Sukhatme
-
Patent number: 5789654Abstract: Disclosed a transgenic non-human mammal whose germ cells and somatic cells contain a knockout mutation in DNA encoding .beta..sub.3 -adrenergic receptor polypeptide.Type: GrantFiled: May 9, 1996Date of Patent: August 4, 1998Assignees: Beth Israel Hospital Association, Centre National de la Recherche ScientifiqueInventors: Bradford B. Lowell, A. Donny Strosberg
-
Patent number: 5776465Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.Type: GrantFiled: June 5, 1995Date of Patent: July 7, 1998Assignees: Beth Israel Hospital Association, Whitehead Institute for Biomedical ResearchInventors: Michael A. O'Donnell, Rosemary B. Duda, William C. DeWolf, Anna Aldovini, Richard A. Young
-
Patent number: 5767073Abstract: The sequence, molecular structure and expression of a cDNA clone, denoted D4, of human and murine origin, preferentially expressed in hematopoietic cells is described herein. The human cDNA clone has been expressed in bacteria and the predicted 24 Kd protein purified. The protein has been used in studies of its biochemical function. As predicted on the basis of sequence, D4 can function as a GDP-dissociation inhibitor of at least several small GTP-binding proteins (CDC42 and rac). The D4 protein was used to generate a polyclonal antibody specific for the protein. The human cDNA was used to obtain several full length murine genomic clones. A clone has been analyzed and sequenced to use for the construction of a gene-targeting vector to produce animals deficient in D4 through disruption of the gene by homologous recombination. These animals can then be used as models for fundamental and applied research on the GTP-binding proteins.Type: GrantFiled: June 1, 1994Date of Patent: June 16, 1998Assignee: Beth Israel Hospital AssociationInventors: Bing Lim, Jean-Michel Lelias, Chaker N. Adra, Jone L. Ko
-
Patent number: 5717062Abstract: Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A.sub.13 and A.sub.17, A.sub.26 and A.sub.30, or A.sub.13 and A.sub.17 and A.sub.26 and A.sub.30.Type: GrantFiled: June 7, 1995Date of Patent: February 10, 1998Assignee: Beth Israel Hospital AssociationInventors: Michael Chorev, Michael Rosenblatt
-
Patent number: 5704369Abstract: The present invention provides non-invasive methods for diagnosing Alzheimer's disease in a living human subject. One method employs a non-invasive automated apparatus which can continuously monitor pupil diameter size over time; repetitively measure pupil diameter size over time for a pre-chosen duration ranging from about less than 1 second to about 5 minutes; and cumulatively record size information as it is obtained over time. A second method employs an apparatus which can repetitively measure pupil constriction velocity for a pre-chosen duration both before and after stimulation by visible light. Both methods require the administration of at least one neural transmitter mediator to a targeted eye of the living subject in an amount insufficient to cause marked changes in pupil diameter size over time in a person who is not afflicted with Alzheimer's disease.Type: GrantFiled: September 22, 1995Date of Patent: January 6, 1998Assignee: Beth Israel Hospital Association, Inc.Inventors: Leonard Scinto, Kirk R. Daffner